GLAXO vs NEULANDLAB: Stock Comparison
GLAXOSMITHKLINE PHARMA LT is the larger company by market capitalisation. GLAXOSMITHKLINE PHARMA LT shows a lower P/E, a higher ROE and a higher dividend yield, while NEULAND LAB shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
GLAXO leads 8; NEULANDLAB leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | GLAXO | NEULANDLAB |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | GLAXO | NEULANDLAB |
|---|---|---|
| Live Price | ₹2,828.4 | ₹23,535 |
| Day Change | -0.44% | -1.11% |
| Volume | 38,428 | 43,901 |
| 52-Week High | ₹3,120.7 | ₹24,225 |
| 52-Week Low | ₹2,088.1 | ₹11,500 |
| Distance from 52W High | -9.37% | -2.85% |
Valuation
| Metric | GLAXO | NEULANDLAB |
|---|---|---|
| Market Cap | ₹47,943 Cr | ₹30,060 Cr |
| P/E Ratio | 44.89x | 60.39x |
| P/B Ratio | 21.14x | 16.04x |
| EPS | ₹14 | ₹115.1 |
| Book Value | ₹134.86 | ₹1,461.02 |
| Dividend Yield | 2.01% | 0.15% |
Growth
| Metric | GLAXO | NEULANDLAB |
|---|---|---|
| Revenue Growth (TTM YoY) | 2.1% | 136.4% |
| EPS Growth (TTM YoY) | 5.7% | 664.4% |
| Qtr Sales Growth | 1.52% | 0% |
| Qtr Profit Growth | -6.38% | 0.21% |
Profitability & Leverage
| Metric | GLAXO | NEULANDLAB |
|---|---|---|
| ROE | 45.34% | 19.46% |
| ROCE | 87.77% | 19.17% |
| Net Margin | 27.29% | 17.99% |
| Operating Margin | 36.86% | 25.29% |
| Debt to Equity | 0x | 0.11x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | GLAXO | NEULANDLAB |
|---|---|---|
| Promoter Holding | 75% | 32.62%▼ 0.01 pp |
| FII Holding | 4.79%▲ 0.17 pp | 21.08%▲ 0.62 pp |
| DII Holding | 7.8%▲ 0.12 pp | 16.51%▲ 0.67 pp |
| Public Holding | 12.41%▼ 0.28 pp | 29.79%▼ 1.28 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GLAXOSMITHKLINE PHARMA LT and NEULAND LAB.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.